No annual revenue total was found in Milestone Pharmaceuticals Inc.'s SEC filings.
Milestone Pharmaceuticals Inc. (MIST) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$49.3 million. As of Jun 30, 2026 it held $170.6 million in cash and investments and $60.1 million in total debt.
Revenue
—
Net income (TTM)
$-84.01M
-51.3% vs year-ago TTM
Operating cash flow (TTM)
$-61.29M
-51.8% vs year-ago TTM
Free cash flow (TTM)
$-61.65M
-52.5% vs year-ago TTM
EPS
$-0.75
-11.9% vs prior year
Dividend per share
None
Shares outstanding
117.67M
+120.5% vs prior year
Net cash
$110.54M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Quebec, Canada
- Headquarters
- Montreal, Quebec, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1408443
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$62.1M | -$42.1M | -$61.1M | -$59.6M | -$43.1M |
| Net income | -$63.1M | -$41.5M | -$59.7M | -$58.4M | -$42.9M |
| Diluted EPS | -$0.75 | -$0.67 | -$1.39 | — | -$1.02 |
| Operating cash flow | -$49.0M | -$28.8M | -$46.4M | -$52.5M | -$33.2M |
| Free cash flow | -$49.3M | -$28.9M | -$46.5M | -$52.7M | — |
| Total assets | $113.6M | $75.5M | $75.2M | $74.5M | $119.8M |
| Total liabilities | $71.8M | $62.4M | $58.5M | $8.1M | $7.2M |
| Stockholders' equity | $41.8M | $13.1M | $16.8M | $66.3M | $112.6M |
| Cash and investments | $106.0M | $69.7M | $66.0M | $64.6M | $114.1M |
| Total debt | $58.4M | $54.8M | $51.8M | $2.5M | $687,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 28, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 3, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 15, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 421 Milestone Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.